← Back
Data updated: Jun 28, 2026
ASCEND THERAPS US
Pharma Pharmaceuticals
ASCEND THERAPS US is a pharmaceutical company with 1 FDA-approved products.
2004
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
ASCEND THERAPS US's Key Drugs
ASCEND THERAPS US's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
ASCEND THERAPS US's Recent FDA Approvals
New NDA/BLA approvals for ASCEND THERAPS US over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ASCEND THERAPS US's Therapeutic Areas
Disease areas where ASCEND THERAPS US has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ASCEND THERAPS US Pipeline Snapshot
Active clinical trials for ASCEND THERAPS US across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2004-02-09
- Latest
- 2024-02-15
- Applications
- 1